Home > Community > Bayer CEO Werner Baumann says company is putting major litigation behind us while highlighting Q2 growth
Upvote

20

Downvote
+ Pharma
Posted by
Mike Miller

Bayer CEO Werner Baumann says company is putting major litigation behind us while highlighting Q2 growth

Bay­er CEO Wern­er Bau­mann high­light­ed “strong op­er­a­tional per­for­mance” on Thurs­day while rais­ing the full-year guid­ance. But be­fore div­ing in­to the de­tails, he sum­ma­rized Bay­er’s plan to set­tle a slate of on­go­ing lit­i­ga­tion.

“We are mak­ing good progress in putting ma­jor lit­i­ga­tion be­hind us,” Bau­mann said on a Q2 call with in­vestors and an­a­lysts.

He added that the com­pa­ny is “con­fi­dent in the lit­i­ga­tion strat­e­gy” when it comes to glyphosate, the ac­tive in­gre­di­ent in the weed­killer Roundup. Bay­er has faced mul­ti­ple cas­es al­leg­ing that Roundup caused can­cer, and re­cent­ly an­nounced a five-point plan to “a clear path to clo­sure of the U.S. glyphosate lit­i­ga­tion.”

The com­pa­ny has al­ready set­tled 107,000 of 138,000 cas­es, ac­cord­ing to its web­site.

“From to­day’s per­spec­tive, we are suf­fi­cient­ly pro­vi­sioned to deal with the cur­rent and al­so the fu­ture cas­es,” Bau­mann said.

Bay­er has faced scruti­ny since clos­ing $30 bil­lion in val­u­a­tion af­ter its $63 bil­lion buy­out of US agri­cul­tur­al gi­ant Mon­san­to in 2018.

Af­ter Roundup de­ba­cle, Bay­er's share­hold­ers vote against man­age­ment pay scheme

As for law­suits al­leg­ing Mon­san­to and oth­er com­pa­nies should be held re­spon­si­ble for en­vi­ron­men­tal im­pacts from car­cino­genic chem­i­cals called poly­chlo­ri­nat­ed biphenyls (PCBs), Bay­er said a class ac­tion set­tle­ment is like­ly com­ing in Q4.

“The opt out pe­ri­od for the class set­tle­ment re­cent­ly ex­pired and we ex­pect to fi­nal­ize the na­tion­al class ac­tion set­tle­ment in quar­ter four,” Bau­mann said.

He al­so said an ar­bi­tra­tion rul­ing is ex­pect­ed soon in its case with BASF, which claimed Bay­er didn’t ful­ly dis­close per­son­nel costs when it ne­go­ti­at­ed as­sets from the crop sci­ence port­fo­lio.

“We ex­pect the de­ci­sion by the ar­bi­tral tri­bunal to be is­sued short­ly,” the com­pa­ny said.

As for the phar­ma busi­ness, sales were slight­ly up thanks to gains from Eylea, Bay­er’s vas­cu­lar en­dothe­lial growth fac­tor (VEGF) in­hibitor used to treat sev­er­al eye-re­lat­ed con­di­tions, in­clud­ing neo­vas­cu­lar (wet) age-re­lat­ed mac­u­lar de­gen­er­a­tion (AMD), mac­u­lar ede­ma fol­low­ing reti­nal vein oc­clu­sion (RVO), di­a­bet­ic mac­u­lar ede­ma (DME) and di­a­bet­ic retinopa­thy (DR).

Eylea earned rough­ly $826 mil­lion last quar­ter (€807 mil­lion), up from $728 mil­lion (€711 mil­lion) in Q2 of 2021.

Bay­er main­tained its con­fi­dence in Eylea de­spite the emer­gence of com­peti­tors, in­clud­ing Roche’s two prod­ucts Susvi­mo and Vabysmo. Back in May, a Spher­ix study re­vealed that while most oph­thal­mol­o­gists have heard of Susvi­mo, a ma­jor­i­ty of the re­spon­dents said they’d turn to Re­gen­eron’s Eylea as a safer and more ac­ces­si­ble op­tion.

Eylea keeps its lead in the reti­nal space as physi­cians re­main hes­i­tant on Roche's Susvi­mo — re­port

How­ev­er, Roche not­ed that phar­ma growth was held back by “price- and vol­ume-re­lat­ed de­clines for Xarel­to that were large­ly due to ten­der pro­ce­dures in Chi­na and the ex­pi­ra­tion of our patent in Brazil.”

Xarel­to earned rough­ly $1.1 bil­lion (€1.1 bil­lion) in Q2, down slight­ly from the near­ly $1.2 bil­lion it raked in sec­ond quar­ter last year.

Con­sumer health sales were up 6.8% this quar­ter, large­ly dri­ven by a 17% growth in al­ler­gy and sales as a high­er num­ber of cold in­ci­dents oc­curred due to less so­cial dis­tanc­ing, the com­pa­ny said.

# Bayer
Related Topic

Related Topic

# Bayer

+
Company Market Cap

Company Market Cap

Name

bayer

Code

BAYRY

Cap

13.37 USD

TOP